Table 3. Adverse events among the liver failure and increased bleeding risk patients in original and matched cohort.
| Endpoints | Original cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|
| RCA-CVVH | No-anticoagulation-CVVH | P-value | RCA-CVVH | No-anticoagulation-CVVH | P-value | |
| Bleeding, n (%) | 4 (5.1) | 7 (4.3) | 0.753 | 3 (5.8) | 4 (4.9) | 1.000 |
| RBC Transfusion (units), mean ± SD | 6.7 ± 5.5 | 3.9 ± 3.5 | 0.318 | 7.6 ± 6.3 | 5.9 ± 3.8 | 0.656 |
| Catheter occlusion, n (%) | 2 (2.5) | 1 (0.6) | 0.251 | 1 (1.9) | 0 (0) | 1.000 |
| TotCa/ionCa > 2.5, n (%) | 4 (5.1) | 0 (0) | 0.004 | 2 (3.8) | 0 (0) | 0.074 |
| Acidosis, pH < 7.35, n (%) | 7 (9.1) | 8 (5.0) | 0.226 | 5(9.6) | 5 (6.1) | 0.450 |
| Alkalosis, pH > 7.45, n (%) | 0 (0) | 0 (0) | 0.237 | 0 (0) | 0 (0) | 0.134 |
RCA, regional citrate anticoagulation; CVVH, continuous venovenous hemofiltration; TotCa/ionCa, total to ionized calcium ratio.